What the Second Circuit Did and Didn't Tell Us About RICO's Reach
His practice includes the representation of drug manufacturers and other commercial entities in industry-wide multi-plaintiff and class action litigation involving alleged price-fixing and other collusive conduct, claims of fraud, violations of RICO, Walker Process patent-based antitrust claims, and in enforcement actions against the sale of illegally imported and diverted drugs and medical devices. Rob also represents drug industry clients in connection with Federal Trade Commission investigations and enforcement actions, and served as co-lead counsel to a major international drug manufacturer in the defense of nationwide litigation challenging industry pricing practices. Rob is also outside counsel to and Corporate Secretary of, the Pharmaceutical Security Institute, Inc., the brand name pharmaceutical industry’s not-for-profit trade organization dedicated to the fight against pharmaceutical counterfeiting.
Outside the pharmaceutical industry, Rob's principal work has been in defending against RICO, False Claims Act, antitrust, and other claims based on federal statutes. Much of this work has involved U.S. litigation against foreign businesses. He is Managing Editor of The World in US Courts: Orrick's Quarterly Review of Decisions Applying US Law to Global Business and Cross-Border Activities.
Rob also has extensive experience representing clients in product safety matters before the U.S. Consumer Product Safety Commission.
Prior to joining Orrick, Rob was a partner in Hughes Hubbard & Reed LLP, where he served as co-chair of the firm’s Pharmaceutical and Healthcare Industry and Product Safety Practice Groups. He was also the Washington, D.C., Office Pro Bono Coordinator.